Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
Public ClinicalTrials.gov record NCT00668200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation
Study identification
- NCT ID
- NCT00668200
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Interventions
- Calcium Dietary Supplement
- Reclast (ZOL446, zoledronic acid) Drug
- Vitamin D Dietary Supplement
Dietary Supplement · Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Oct 31, 2012
- Completion
- Oct 31, 2012
- Last update posted
- Mar 5, 2015
2008 – 2012
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85012 | — |
| Novartis Investigative Site | Tucson | Arizona | 85723-0001 | — |
| Novartis Investigative Site | Gainesville | Georgia | 30501 | — |
| Novartis Investigative Site | Detroit | Michigan | 48236 | — |
| Novartis Investigative Site | Syracuse | New York | 13210-2306 | — |
| Novartis Investigative Site | Providence | Rhode Island | 02908 | — |
| Novartis Investigative Site | Dallas | Texas | 75216 | — |
| Novartis Investigative Site | Waco | Texas | 76708 | — |
| Novartis Investigative Site | Madison | Wisconsin | 53705-3611 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00668200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2015 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00668200 live on ClinicalTrials.gov.